| Name | Arecor Therapeutics |
|---|---|
| Epic | AREC |
| Isin | GB00BMWLM973 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 58.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £22.09 | Debt ratio | n/a |
| Shares in issue | 37.76 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -130.09 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -28 | 52-week high / low | 57.00p / 170.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Arecor Therapeutics |
|---|---|
| Address | Chesterford Research Park, Little Chesterford, Saffron Walden, United Kingdom, CB10 1XL |
| Telephone | +44 (0)1223 426060 |
| Website | https://arecor.com/ |
| Director | Position |
|---|---|
| Ms Sarah Jennifer Howell | CEO |
| Mr David Ellam | CFO |
| Mr Alan Edward Smith | Non-Executive Director |
| Mr Andrew Richards | Non-Executive Chairman |
| Mr Mohammed Sohail Fazeli | Independent Non-Executive Director |
| Ms Christine Helen Soden | Independent Non-Executive Director |
| Mr Jeremy Lewis Morgan | Independent Non-Executive Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 3.3 | 3.4 | 0.03 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 4.21 | 4.29 | 0.41 |
| Inventory / work in progress | 0.77 | 1.13 | n/a |
| Trade and other receivables | 3.65 | 3.54 | 2.2 |
| Cash and equivalents | 5.09 | 4.76 | 18.32 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 15.38 | 21.77 | 20.92 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 5.15 | 3.73 | 2.27 |
| Long term liabilities | 0.7 | 0.58 | 0.11 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 5.85 | 4.31 | 2.37 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 9.53 | 17.45 | 18.55 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.31 | 0.31 | 0.28 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -34.72 | -26.18 | -17.05 |
| Share premium account | 28.98 | 28.98 | 23.35 |
| Total equity | 9.53 | 17.45 | 18.55 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -9.18 | -10.63 | -6.44 |
| Pre-tax profit | -8.9 | -10.54 | -6.95 |